← Leaderboards
Andrew Charles Harris
Hennepin Healthcare Research Institute
$4,665,546
Attributed
$9,068,241
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,068,241 · 7
By mechanism
R01$5,312,659 · 3
U01$3,133,931 · 1
R21$358,800 · 1
R03$221,479 · 1
F32$41,372 · 1
Top collaborators
- Mark G Lesage9 shared
- Jonathan Gewirtz7 shared
Most similar at Hennepin Healthcare Research Institute
Same institution · by research overlap
- John Richard Smethells$1,082,038
Others in their field
Top investigators on “Addiction”
- Wafaa M. El-Sadr · Columbia University Health Sciences$122,006,808
- Sten H Vermund · University Of Alabama At Birmingham$115,253,143
- Jeffrey H Samet · Boston University Medical Campus$108,787,548
- Myron S Cohen · Family Health International$101,800,876
- Sharon L. Walsh · University Of Kentucky$92,602,816
- Jeffrey S Flier · Beth Israel Deaconess Medical Center$89,041,364
Research focus
AddictionExposure ToSelf AdministrationBehavioralRattusPharmaceutical PreparationsAnimal ModelExhibitsNicotinePre-ClinicalSelf StimulationPsychological ReinforcementPreventionAnimalsTobaccoDoseCigaretteAreaRegulationElectronic CigaretteFormulationInnovationAttenuatedAcute
Grant awards (19)
Effects of maternal e-cigarette aerosol exposure on nicotine's addiction-related behavioral and neurobiological effects in offspring$692,419
R01 · FY2025 · DA
Identifying genomic loci related to vulnerability to opioid addiction$662,194
U01 · FY2024 · DA
Comparative neurobehavioral pharmacology of combusted and non-combusted tobacco products$633,574
R01 · FY2024 · DA
Comparative neurobehavioral pharmacology of combusted and non-combusted tobacco products$641,826
R01 · FY2023 · DA
Identifying genomic loci related to vulnerability to opioid addiction$612,928
U01 · FY2023 · DA
Comparative neurobehavioral pharmacology of combusted and non-combusted tobacco products$683,052
R01 · FY2022 · DA
Identifying genomic loci related to vulnerability to opioid addiction$611,166
U01 · FY2022 · DA
Comparative neurobehavioral pharmacology of combusted and non-combusted tobacco products$702,233
R01 · FY2021 · DA
Identifying genomic loci related to vulnerability to opioid addiction$610,053
U01 · FY2021 · DA
Comparative neurobehavioral pharmacology of combusted and non-combusted tobacco products$694,783
R01 · FY2020 · DA
Identifying genomic loci related to vulnerability to opioid addiction$637,590
U01 · FY2020 · DA
Animal models to inform FDA tobacco regulation: Assessing the relative abuse liability of different classes of tobacco products$411,165
R01 · FY2020 · DA · contact PI
Animal models to inform FDA tobacco regulation: Assessing the relative abuse liability of different classes of tobacco products$421,054
R01 · FY2019 · DA · contact PI
Animal models to inform FDA tobacco regulation: Assessing the relative abuse liability of different classes of tobacco products$432,553
R01 · FY2018 · DA · contact PI
Animal models for evaluating the relative abuse liability of electronic cigarettes$111,147
R03 · FY2017 · DA · contact PI
A novel approach for identifying addiction vulnerability in animals.$167,305
R21 · FY2016 · DA
Animal models for evaluating the relative abuse liability of electronic cigarettes$110,332
R03 · FY2016 · DA · contact PI
A novel approach for identifying addiction vulnerability in animals.$191,495
R21 · FY2015 · DA
Compensation of Nicotine Self-Administration$41,372
F32 · FY2007 · DA · contact PI